Biomedical Research and Therapy <p>Biomedical Research and Therapy (ISSN 2198-4093)<strong>&nbsp;</strong>is the major forum for basic and translational research into therapies. An international peer-reviewed journal, it publishes high quality open access research articles with a special emphasis on basic, translational and clinical research into molecular therapeutics and cellular therapies, including animal models and clinical trials. The journal also provides reviews, viewpoints, commentaries and reports.&nbsp;Biomedical Research and Therapy's Editorial Policies follow the recommendations of the <a href="" target="_blank" rel="noopener">International Committee of Medical Journal Editors (ICMJE)</a>, <a href="" target="_blank" rel="noopener">the World Association of Medical Editors (WAME)</a>, and&nbsp;<a href="" target="_blank" rel="noopener">the Committee on Publication Ethics (COPE)</a> for guidance on policies and procedures related to publication ethics.&nbsp;The journal is published monthly, <em><strong>12 issues</strong></em> per year.</p> BioMedPress (BMP) en-US Biomedical Research and Therapy 2198-4093 <p>Copyright The Author(s) 2017. This article is published with open access by <a href="" target="_blank">BioMedPress</a>. This article is distributed under the terms of the&nbsp;<a href="" target="_blank">Creative Commons Attribution License (CC-BY 4.0)</a> which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.&nbsp;</p> Ki-67 status in patients with primary breast cancer and its relationship with other prognostic factors <p><strong>Introduction</strong>: Breast cancer (BC) is the most common cancer in women and is the second most common cause of fatality in patients with cancer in the world. Cell proliferation plays an important role in the clinical behavior of invasive BC. We aimed to assess the status of Ki-67 in patients with primary breast cancer and evaluate the association of this tumor marker with other clinico-pathologic and prognostic factors.</p> <p><strong>Methods</strong>: The current study recruited 220 patients with primary BC admitted to the oncology clinic of the Tabriz University of Medical Sciences. We evaluated Ki-67 IHC slides and reported the Ki-67 status and its relationship with other prognostic factors in breast cancer patients. Among 220 patients, 63.3% developed grade 2 tumors, and 63.8% were younger than 50-year-olds. 117 cases (53%) were Ki-67 positive with more than 1% tumor nuclei stained, and 53 cases (24%) had tumors with more than 15% of Ki-67 expression.</p> <p><strong>Results</strong>: There was no correlation between Ki-67 and patient's age (Spearman rho = 0.375, tau Kendall = 0.374), tumor size (Spearman rho = 0.558, tau Kendall = 0.548) and grade (Spearman rho = 0.570, tau Kendall = 0.568), however, there was a marginally significant relationship between lymph node status and Ki-67 expression (Spearman rho = 0.077, tau Kendall = 0.079). Based on the Mann -Whitney test, there was a significant correlation between the expression of estrogen receptor (ER) and progesterone receptor (PR) with Ki-67.</p> <p><strong>Conclusion</strong>: A reliable estimation of different prognostic factors in BC patients is required for the selection of an optimal therapeutic strategy. The attention has been focused on the markers of tumor biology.</p> <p>&nbsp;</p> Touraj Asvadi Kermani Iraj Asvadi Kermani Zhaleh Faham Roya Dolatkhah ##submission.copyrightStatement## 2019-02-17 2019-02-17 6 2 2986 2991 10.15419/bmrat.v6i2.520 title description none g A proposition for a cancer treatment study using radioactive metal co-factor enzymes <p>Cancer is a serious pathological condition of abnormal cells are gathered in tumors in the body's tissues or organs. Due to their accelerated metabolism, cancer cells require a great demand for energy, protein (cell structure substrates), and metabolic enzyme activity. If the body does not respond adequately to this demand, the metabolic processes of cancer cells will be hampered, and their growth will be limited or even stopped. It is possible to control the metabolic processes of the cancerous tumors by performing one or more of the following approaches: stopping the energy and cell structure substrate supply, inhibiting enzymic activity, and/or destroying cancer cells with external agents (such as radiation and/or chemicals). These approaches have been investigated either in single or combination modes, but so far the results obtained have not been on par with expectations. In this paper, we propose a method of cancer treatment which entails the use of a radioisotope instead of stable metal to break down the structure of metal co-factor enzyme and to deactivate its catalytic function. With a judicious choice of the metal radioisotope, this method is even able to perform all the above-mentioned approaches, and at the same time, giving a much better efficacy in cancer treatment.</p> <p>&nbsp;</p> Luyen Van Tran ##submission.copyrightStatement## 2019-02-17 2019-02-17 6 2 2983 2985 10.15419/bmrat.v6i2.519 title description none g